Chronic vagus nerve stimulation: A new and promising therapeutic approach for chronic heart failure

Gaetano M. De Ferrari, Harry J G M Crijns, Martin Borggrefe, Goran Milasinovic, Jan Smid, Markus Zabel, Antonello Gavazzi, Antonio Sanzo, Robert Dennert, Juergen Kuschyk, Srdjan Raspopovic, Helmut Klein, Karl Swedberg, Peter J. Schwartz

Research output: Contribution to journalArticle

296 Citations (Scopus)

Abstract

Aims In chronic heart failure (CHF), reduced vagal activity correlates with increased mortality and acute decompensation. Experimentally, chronic vagus nerve stimulation (VNS) improved left ventricular (LV) function and survival; clinically, it is used for the treatment of drug-refractory epilepsy. We assessed safety and tolerability of chronic VNS in symptomatic CHF patients, using a novel implantable nerve stimulation system. The secondary goal was to obtain preliminary data on clinical efficacy. Methods and resultsThis multi-centre, open-label phase II, two-staged study (8-patient feasibility phase plus 24-patient safety and tolerability phase) enrolled 32 New York Heart Association (NYHA) class IIIV patients [age 56 ± 11 years, LV ejection fraction (LVEF) 23 ± 8]. Right cervical VNS with CardioFit (BioControl Medical) implantable system started 24 weeks after implant, slowly raising intensity; patients were followed 3 and 6 months thereafter with optional 1-year follow-up. Overall, 26 serious adverse events (SAEs) occurred in 13 of 32 patients (40.6), including three deaths and two clearly device-related AEs (post-operative pulmonary oedema, need of surgical revision). Expected non-serious device-related AEs (cough, dysphonia, and stimulation-related pain) occurred early but were reduced and disappeared after stimulation intensity adjustment. There were significant improvements (P <0.001) in NYHA class quality of life, 6-minute walk test (from 411 ± 76 to 471 ± 111 m), LVEF (from 22 ± 7 to 29 ± 8), and LV systolic volumes (P 0.02). These improvements were maintained at 1 year. ConclusionsThis open-label study shows that chronic VNS in CHF patients with severe systolic dysfunction may be safe and tolerable and may improve quality of life and LV function. A controlled clinical trial appears warranted.

Original languageEnglish
Pages (from-to)847-855
Number of pages9
JournalEuropean Heart Journal
Volume32
Issue number7
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Vagus Nerve Stimulation
Heart Failure
Left Ventricular Function
Therapeutics
Quality of Life
Social Adjustment
Dysphonia
Equipment and Supplies
Controlled Clinical Trials
Pulmonary Edema
Patient Safety
Reoperation
Cough
Stroke Volume
Safety
Pain
Survival
Mortality

Keywords

  • Autonomic nervous system
  • Heart failure
  • Non-pharmacologic therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chronic vagus nerve stimulation : A new and promising therapeutic approach for chronic heart failure. / De Ferrari, Gaetano M.; Crijns, Harry J G M; Borggrefe, Martin; Milasinovic, Goran; Smid, Jan; Zabel, Markus; Gavazzi, Antonello; Sanzo, Antonio; Dennert, Robert; Kuschyk, Juergen; Raspopovic, Srdjan; Klein, Helmut; Swedberg, Karl; Schwartz, Peter J.

In: European Heart Journal, Vol. 32, No. 7, 04.2011, p. 847-855.

Research output: Contribution to journalArticle

De Ferrari, GM, Crijns, HJGM, Borggrefe, M, Milasinovic, G, Smid, J, Zabel, M, Gavazzi, A, Sanzo, A, Dennert, R, Kuschyk, J, Raspopovic, S, Klein, H, Swedberg, K & Schwartz, PJ 2011, 'Chronic vagus nerve stimulation: A new and promising therapeutic approach for chronic heart failure', European Heart Journal, vol. 32, no. 7, pp. 847-855. https://doi.org/10.1093/eurheartj/ehq391
De Ferrari, Gaetano M. ; Crijns, Harry J G M ; Borggrefe, Martin ; Milasinovic, Goran ; Smid, Jan ; Zabel, Markus ; Gavazzi, Antonello ; Sanzo, Antonio ; Dennert, Robert ; Kuschyk, Juergen ; Raspopovic, Srdjan ; Klein, Helmut ; Swedberg, Karl ; Schwartz, Peter J. / Chronic vagus nerve stimulation : A new and promising therapeutic approach for chronic heart failure. In: European Heart Journal. 2011 ; Vol. 32, No. 7. pp. 847-855.
@article{ee233c483fc3475f85eeea9faaa22865,
title = "Chronic vagus nerve stimulation: A new and promising therapeutic approach for chronic heart failure",
abstract = "Aims In chronic heart failure (CHF), reduced vagal activity correlates with increased mortality and acute decompensation. Experimentally, chronic vagus nerve stimulation (VNS) improved left ventricular (LV) function and survival; clinically, it is used for the treatment of drug-refractory epilepsy. We assessed safety and tolerability of chronic VNS in symptomatic CHF patients, using a novel implantable nerve stimulation system. The secondary goal was to obtain preliminary data on clinical efficacy. Methods and resultsThis multi-centre, open-label phase II, two-staged study (8-patient feasibility phase plus 24-patient safety and tolerability phase) enrolled 32 New York Heart Association (NYHA) class IIIV patients [age 56 ± 11 years, LV ejection fraction (LVEF) 23 ± 8]. Right cervical VNS with CardioFit (BioControl Medical) implantable system started 24 weeks after implant, slowly raising intensity; patients were followed 3 and 6 months thereafter with optional 1-year follow-up. Overall, 26 serious adverse events (SAEs) occurred in 13 of 32 patients (40.6), including three deaths and two clearly device-related AEs (post-operative pulmonary oedema, need of surgical revision). Expected non-serious device-related AEs (cough, dysphonia, and stimulation-related pain) occurred early but were reduced and disappeared after stimulation intensity adjustment. There were significant improvements (P <0.001) in NYHA class quality of life, 6-minute walk test (from 411 ± 76 to 471 ± 111 m), LVEF (from 22 ± 7 to 29 ± 8), and LV systolic volumes (P 0.02). These improvements were maintained at 1 year. ConclusionsThis open-label study shows that chronic VNS in CHF patients with severe systolic dysfunction may be safe and tolerable and may improve quality of life and LV function. A controlled clinical trial appears warranted.",
keywords = "Autonomic nervous system, Heart failure, Non-pharmacologic therapy",
author = "{De Ferrari}, {Gaetano M.} and Crijns, {Harry J G M} and Martin Borggrefe and Goran Milasinovic and Jan Smid and Markus Zabel and Antonello Gavazzi and Antonio Sanzo and Robert Dennert and Juergen Kuschyk and Srdjan Raspopovic and Helmut Klein and Karl Swedberg and Schwartz, {Peter J.}",
year = "2011",
month = "4",
doi = "10.1093/eurheartj/ehq391",
language = "English",
volume = "32",
pages = "847--855",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Chronic vagus nerve stimulation

T2 - A new and promising therapeutic approach for chronic heart failure

AU - De Ferrari, Gaetano M.

AU - Crijns, Harry J G M

AU - Borggrefe, Martin

AU - Milasinovic, Goran

AU - Smid, Jan

AU - Zabel, Markus

AU - Gavazzi, Antonello

AU - Sanzo, Antonio

AU - Dennert, Robert

AU - Kuschyk, Juergen

AU - Raspopovic, Srdjan

AU - Klein, Helmut

AU - Swedberg, Karl

AU - Schwartz, Peter J.

PY - 2011/4

Y1 - 2011/4

N2 - Aims In chronic heart failure (CHF), reduced vagal activity correlates with increased mortality and acute decompensation. Experimentally, chronic vagus nerve stimulation (VNS) improved left ventricular (LV) function and survival; clinically, it is used for the treatment of drug-refractory epilepsy. We assessed safety and tolerability of chronic VNS in symptomatic CHF patients, using a novel implantable nerve stimulation system. The secondary goal was to obtain preliminary data on clinical efficacy. Methods and resultsThis multi-centre, open-label phase II, two-staged study (8-patient feasibility phase plus 24-patient safety and tolerability phase) enrolled 32 New York Heart Association (NYHA) class IIIV patients [age 56 ± 11 years, LV ejection fraction (LVEF) 23 ± 8]. Right cervical VNS with CardioFit (BioControl Medical) implantable system started 24 weeks after implant, slowly raising intensity; patients were followed 3 and 6 months thereafter with optional 1-year follow-up. Overall, 26 serious adverse events (SAEs) occurred in 13 of 32 patients (40.6), including three deaths and two clearly device-related AEs (post-operative pulmonary oedema, need of surgical revision). Expected non-serious device-related AEs (cough, dysphonia, and stimulation-related pain) occurred early but were reduced and disappeared after stimulation intensity adjustment. There were significant improvements (P <0.001) in NYHA class quality of life, 6-minute walk test (from 411 ± 76 to 471 ± 111 m), LVEF (from 22 ± 7 to 29 ± 8), and LV systolic volumes (P 0.02). These improvements were maintained at 1 year. ConclusionsThis open-label study shows that chronic VNS in CHF patients with severe systolic dysfunction may be safe and tolerable and may improve quality of life and LV function. A controlled clinical trial appears warranted.

AB - Aims In chronic heart failure (CHF), reduced vagal activity correlates with increased mortality and acute decompensation. Experimentally, chronic vagus nerve stimulation (VNS) improved left ventricular (LV) function and survival; clinically, it is used for the treatment of drug-refractory epilepsy. We assessed safety and tolerability of chronic VNS in symptomatic CHF patients, using a novel implantable nerve stimulation system. The secondary goal was to obtain preliminary data on clinical efficacy. Methods and resultsThis multi-centre, open-label phase II, two-staged study (8-patient feasibility phase plus 24-patient safety and tolerability phase) enrolled 32 New York Heart Association (NYHA) class IIIV patients [age 56 ± 11 years, LV ejection fraction (LVEF) 23 ± 8]. Right cervical VNS with CardioFit (BioControl Medical) implantable system started 24 weeks after implant, slowly raising intensity; patients were followed 3 and 6 months thereafter with optional 1-year follow-up. Overall, 26 serious adverse events (SAEs) occurred in 13 of 32 patients (40.6), including three deaths and two clearly device-related AEs (post-operative pulmonary oedema, need of surgical revision). Expected non-serious device-related AEs (cough, dysphonia, and stimulation-related pain) occurred early but were reduced and disappeared after stimulation intensity adjustment. There were significant improvements (P <0.001) in NYHA class quality of life, 6-minute walk test (from 411 ± 76 to 471 ± 111 m), LVEF (from 22 ± 7 to 29 ± 8), and LV systolic volumes (P 0.02). These improvements were maintained at 1 year. ConclusionsThis open-label study shows that chronic VNS in CHF patients with severe systolic dysfunction may be safe and tolerable and may improve quality of life and LV function. A controlled clinical trial appears warranted.

KW - Autonomic nervous system

KW - Heart failure

KW - Non-pharmacologic therapy

UR - http://www.scopus.com/inward/record.url?scp=79953699358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953699358&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehq391

DO - 10.1093/eurheartj/ehq391

M3 - Article

C2 - 21030409

AN - SCOPUS:79953699358

VL - 32

SP - 847

EP - 855

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 7

ER -